{"id":14243,"date":"2026-05-19T11:04:21","date_gmt":"2026-05-19T03:04:21","guid":{"rendered":"https:\/\/vibrojet-tech.com\/?post_type=docs&p=14243"},"modified":"2026-05-26T09:14:23","modified_gmt":"2026-05-26T01:14:23","password":"","slug":"usefulness-of-kit-mutant-transcript-levels-for-monitoring-measurable-residual-disease-3","status":"publish","type":"docs","link":"https:\/\/vibrojet-tech.com\/?docs=usefulness-of-kit-mutant-transcript-levels-for-monitoring-measurable-residual-disease-3","title":{"rendered":"Usefulness of KIT mutant transcript levels for monitoring measurable residual disease"},"content":{"rendered":"\n
\n
\n

Hematol Oncol.\u00a0<\/p>\n\n\n\n

2024 Mar<\/p>\n<\/div>\n\n\n\n

\n

DOI:<\/p>\n\n\n\n

10.1002\/hon.3264<\/p>\n<\/div>\n\n\n\n

Yuan Sun 1 2<\/sup>, Xu Wang 1<\/sup>, Wen-Min Chen 1<\/sup>, Yue Hao 1<\/sup>, Ling-Di Li 1<\/sup>, Jin-Ying Li 1<\/sup>, Kai Sun 1<\/sup>, Zong-Yan Shi 1<\/sup>, Hao Jiang 1<\/sup>, Qian Jiang 1<\/sup>, Xiao-Jun Huang 1<\/sup>, Ya-Zhen Qin 1<\/sup><\/p>\n\n\n\n

\n\n\n\n

Abstract<\/h2>\n\n\n\n

In addition to RUNX1<\/em>::RUNX1T1<\/em> transcript levels, measurable residual disease monitoring using KIT<\/em> mutant (KITmut<\/sup>) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KITmut<\/sup> transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KITmut<\/sup> (D816V\/H\/Y or N822K) were tested for KITmut<\/sup> transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KITmut<\/sup> were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KITmut<\/sup>-high (KIT_H) group and the KITmut<\/sup>-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (p<\/em> = 0.0040 and 0.021, respectively) and Course 2 consolidation (p<\/em> = 0.018 and 0.011, respectively) but not at diagnosis and CR. The < 3-log reduction in the RUNX1<\/em>::RUNX1T1<\/em> transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with > 3-log reduction in the RUNX1<\/em>::RUNX1T1<\/em> transcript levels (11\/45; 24.4 %) had similar RFS as that of patients with < 3-log reduction in the RUNX1<\/em>::RUNX1T1<\/em> transcript levels. The combination of KITmut<\/sup> and RUNX1<\/em>::RUNX1T1<\/em> transcript levels after Course 2 consolidation may improve risk stratification in t (8; 21) AML patients with KIT<\/em> mutation.<\/p>\n\n\n\n

\n

Tag<\/strong>s:<\/h2>\n\n\n\n

KIT mutant transcript levels; digital PCR; measurable residual disease; relapse; t (8; 21) AML<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Assesses KIT-mutant transcript levels for measurable residual disease monitoring, supporting molecular quantification workflows in hematologic malignancy follow-up.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"footnotes":""},"doc_category":[32],"doc_tag":[],"class_list":["post-14243","docs","type-docs","status-publish","hentry","doc_category-clinical-translational-evidence"],"year_month":"2026-05","word_count":296,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"root","author_nicename":"root","author_url":"https:\/\/vibrojet-tech.com\/?author=1"},"doc_category_info":[{"term_name":"Clinical & Translational Evidence","term_url":"https:\/\/vibrojet-tech.com\/?doc_category=clinical-translational-evidence"}],"doc_tag_info":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=\/wp\/v2\/docs\/14243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=\/wp\/v2\/docs"}],"about":[{"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=\/wp\/v2\/types\/docs"}],"author":[{"embeddable":true,"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14243"}],"version-history":[{"count":3,"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=\/wp\/v2\/docs\/14243\/revisions"}],"predecessor-version":[{"id":14832,"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=\/wp\/v2\/docs\/14243\/revisions\/14832"}],"wp:attachment":[{"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14243"}],"wp:term":[{"taxonomy":"doc_category","embeddable":true,"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdoc_category&post=14243"},{"taxonomy":"doc_tag","embeddable":true,"href":"https:\/\/vibrojet-tech.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdoc_tag&post=14243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}